Fuzuloparib prolongs progression-free survival in HER2 negative metastatic breast cancer
A benefit was observed in women with germline BRCA1/2 mutations when treated with the PARP inhibitor alone or in combination with apatinib
Cancer Control Principles
How much ‘green’ is cancer research?
Clinical trials have an impact on the environment, and novel approaches may help researchers reshape their activities toward a greater sustainability
Adjuvant immunotherapy improves overall survival in renal-cell carcinoma
Updated results from the KEYNOTE-564 trial confirm the role of pembrolizumab after surgery
Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC
The tyrosine kinase inhibitor showed to prolong disease-free survival as compared to chemotherapy and clinically meaningful benefit with respect to CNS disease–free survival
Treating colorectal cancer in the biomarker era – what's next?
In an interview, Prof. Julien Taieb comments on the major advances from colorectal cancer research which are driving the development of molecular-based therapies
Breast cancer: is the future of PARP inhibitors bright?
Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered
Liquid biopsy: may ctDNA tumour fraction help interpret negative results?
A study illustrates a methodology that shows promise to distinguish true negative liquid biopsy results from indeterminate results that may benefit from follow-up tissue testing
Early breast cancer: higher quality of life reported with a personalised follow-up
A nurse-led follow-up strategy including self-management interventions, use of patient-reported outcomes and phone consultations also resulted in lower fear of recurrence, anxiety and depression
Research in upper gastrointestinal cancers makes a leap forward
In the last few years, study findings have changed clinical practice and offered new opportunities of care to many patients
Colorectal cancer screening: performance of a blood-based test is promising
A study reports high sensitivity and specificity of a cell-free DNA blood-based assay compared to colonoscopy